Clinical trials & development

RSV drug clears Phase I

RSV drug clears Phase I

A compound targetting respiratory syncytial virus - a major threat
to immunocompromised patients - has completed Phase I trials,
raising hopes of the first effective treatment for the virus,
writes Wai Lang Chu.

Follow us

Products

View more

Webinars